chevron_leftBack
As of 5 June 2026, Elixiron Immunotherapeutics (Cayman) Ltd. has a market cap of $321.0M USD, ranking #18184 globally and #719 in Taiwan.
It ranks #1655 in the Healthcare sector, and #598 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$321.0MUSD
10.1B TWD
Enterprise Value
$300.29MUSD
9.45B TWD
Revenue (TTM)
$32.62KUSD
1.03M TWD
EBITDA (TTM)
-$6.96MUSD
-218.83M TWD
Net Income (TTM)
-$43.37MUSD
-1.36B TWD
PS Ratio
9841.8
PB Ratio
14.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Hung-Kai Chen
open_in_new
Founded
2017
Website
elixiron.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.9% | -4% | 5.3% | 72% | 47% | 47% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
7871
ISIN: KYG3106D1016
Shares Out.:
Shares Outstanding:
134.278M1
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
75.20 TWD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Elixiron Immunotherapeutics (Cayman) Ltd.
Elixiron Immunotherapeutics (Cayman) Limited engages in the development of precision-targeted immunotherapy drugs in Shanghai, Taipei, the United States and Switzerland. It develops EI-1071, a small molecule inhibitor of CSF-1R used for the treatment of Alzheimer's disease and amyotrophic lateral sclerosis; EI-001 for the treatment of vitiligo and Hemophagocytic Lymphohistiocytosis (HLH); and EI-012, a monoclonal antibody and EI-220 mRNA for the treatment of cancer. Elixiron Immunotherapeutics (Cayman) Limited was incorporated in 2017 and is headquartered in Taipei, Taiwan.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TWSE: 6446
|
$7.8B
2K%
245.34B TWD
|
48.6
|
|
TWSE: 1795
|
$1.84B
474%
57.95B TWD
|
12.2
|
|
TPEX: 4123
|
$925.55M
188%
29.11B TWD
|
3.4
|
|
TPEX: 6535
|
$809.3M
152%
25.46B TWD
|
-
|
|
TPEX: 4743
|
$789.12M
146%
24.82B TWD
|
-
|
|
TPEX: 4105
|
$584.14M
82%
18.38B TWD
|
11.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
237K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
170K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
112K%
|
97.4
|
|
SIX: RO
|
$323.4B
101K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.25B
90K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$276.26B
86K%
218.9B CHF
|
20.5
|
chevron_leftBack